LumiThera
Poulsbo, US · Founded 2013 · Delaware corporation · 4 known investors
Find your way into LumiThera
144 people in our graph share verified history with the LumiThera team — schools, employers, funds. One of them is your warm intro.
Paul Osmundsonunlockedknows Scott Bradley · together at Colorado State University
×10knows the team · via Colorado State University
knows the team · via Alcon
LumiThera develops the Valeda Light Delivery System, an FDA-authorized photobiomodulation (PBM) device that applies multiple light wavelengths to treat early and intermediate dry age-related macular degeneration (AMD). The non-invasive treatment is intended for eyecare practitioners to help patients maintain or improve visual acuity.
Founders & leadership
TP
Tracy PuckettExecutive
CT
Clark TedfordinExecutive
SB
Scott BradleyinExecutiveScott Bradley is an Executive Officer at LumiThera, which develops the Valeda Light Delivery System, an FDA-authorized photobiomodulation device for treating early and intermediate dry age-related macular degeneration. He brings over 25 years of experience in medical device product development, including design and management across research, pre-clinical studies, clinical trials, and commercial launches.
DM
Duane MorrisoninExecutive
CC
Cindy CroissantExecutive
RM
Ryan MontecuccoExecutive
AT
Art TaylorNamed on SEC filing
Board
DB
Daniel BertholetBoard director
YY
Yang YigangBoard director
SC
Shupeng CaoBoard director
GM
Graham MerryBoard director
JS
Jackson StreeterBoard director
Investors · 4
Funding
SEC filings, press & company announcements$25.5M disclosed across 9 of 11 rounds · 2014–2024
- Undisclosed amountSeries CJul 2020Source ↗
▶$10MraisedFeb 2025 · 58 investors · Other TechnologyRule 506(b)
▶$10MraisedFeb 2025 · 58 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Tracy PuckettExecutive Officer
- Daniel BertholetDirector
- Clark TedfordExecutive Officer, Director
- Jackson StreeterDirector
- Scott BradleyExecutive Officer
- Duane MorrisonExecutive Officer
- Cindy CroissantExecutive Officer
- Ryan MontecuccoExecutive Officer
- Yang YigangDirector
- Shupeng CaoDirector
- Offering amount
- $10M
- Amount sold
- $10M
- Minimum investment
- $10K
- Sales commissions
- $22.7K
- Placement agents
- Entoro Securities
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$820KraisedSep 2022 · 7 investors · Other TechnologyRule 506(b)
▶$820KraisedSep 2022 · 7 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Joseph FontanettaDirector
- Cindy CroissantExecutive Officer
- Shupeng CaoDirector
- Daniel BertholetDirector
- Duane MorrisonExecutive Officer
- Tracy PuckettExecutive Officer
- Todd ChristieDirector
- Clark TedfordExecutive Officer, Director
- Scott BradleyExecutive Officer
- Jackson StreeterDirector
- Ryan MontecuccoExecutive Officer
- Yang YigangDirector
- Offering amount
- $2M
- Amount sold
- $820K
- Minimum investment
- $25K
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.5MraisedOct 2021 · 56 investors · Other TechnologyRule 506(b)
▶$4.5MraisedOct 2021 · 56 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Duane MorrisonExecutive Officer
- Scott BradleyExecutive Officer
- Cindy CroissantExecutive Officer
- Yang YigangDirector
- Clark TedfordExecutive Officer, Director
- Ryan MontecuccoExecutive Officer
- Daniel BertholetDirector
- Offering amount
- $8.1M
- Amount sold
- $4.5M
- Minimum investment
- $15K
- Finders' fees
- $101.1K
- Placement agents
- Entoro Securities
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedAug 2019 · 8 investors · Other TechnologyRule 506(b)
▶$1.1MraisedAug 2019 · 8 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- YIGANG YANGDirector
- CLARK TEDFORDExecutive Officer, Director
- ARTHUR TAYLORDirector
- Offering amount
- $10M
- Amount sold
- $1.1M
- Minimum investment
- $10K
- Sales commissions
- $7K
- Placement agents
- COVA CAPITAL PARTNERS LLC
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$100KraisedMar 2019 · 1 investors · Other TechnologyRule 506(b)
▶$100KraisedMar 2019 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- YIGANG YANGDirector
- CLARK TEDFORDExecutive Officer, Director
- ARTHUR TAYLORDirector
- Offering amount
- $2M
- Amount sold
- $100K
- Minimum investment
- $50K
- Sales commissions
- $7K
- Placement agents
- KEVIN CODY
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedJan 2019 · 13 investors · Other Health CareRule 506(b)
▶$2MraisedJan 2019 · 13 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Art TaylorDirector
- Yang YigangDirector
- Clark TedfordExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- Minimum investment
- $10K
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedAug 2018 · 18 investors · Other TechnologyRule 506(b)
▶$1.6MraisedAug 2018 · 18 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Art TaylorDirector
- Yang YigangDirector
- Clark TedfordExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $1.6M
- Minimum investment
- $25K
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$5MraisedOct 2017 · 51 investors · Other Health CareRule 506(b)
▶$5MraisedOct 2017 · 51 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Art TaylorDirector
- Clark TedfordExecutive Officer, Director
- Offering amount
- $6.6M
- Amount sold
- $5M
- Minimum investment
- $10K
- Sales commissions
- $7K
- Proceeds to insiders
- $240K
- Placement agents
- Robert Brisotti
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $396K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $356.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does LumiThera do?
- LumiThera develops the Valeda Light Delivery System, an FDA-authorized photobiomodulation (PBM) device that applies multiple light wavelengths to treat early and intermediate dry age-related macular degeneration (AMD). The non-invasive treatment is intended for eyecare practitioners to help patients maintain or improve visual acuity.
- Who are LumiThera's investors?
- LumiThera's investors include 3E Bioventures Capital, Life Sciences Greenhouse Investments, Imagine Ventures, Keiretsu Capital.
- How much funding has LumiThera raised?
- LumiThera has disclosed $25.5M raised across 9 of its 11 known rounds.
- Where is LumiThera headquartered?
- LumiThera is headquartered in Poulsbo, US.